Skip to main content
. Author manuscript; available in PMC: 2012 Oct 4.
Published in final edited form as: Ann Rheum Dis. 2010 Nov 15;70(2):309–314. doi: 10.1136/ard.2010.132613

Table 1.

Variables selected by consensus (≥80%) during second round of the Delphi survey

CAPS
Variables FMF (%) TRAPS (%) MKD (%) FCAS (%) MWS (%) NOMID (%)
Fatigue 82 81 87 87 82
Number of days of illness in the past 3 months 94 88 100 93 87 82
Intensity of attacks 89 81
Arthritis 100
Arthralgia 87 80 87
Measure of joint damage 94
Presence absence of skin rash 94 81 82 100 100 88
Intensity of skin rash 93 87 88
Frequency of skin rash 87 80
Number of days with skin rash in a month 93 93 82
Chest symptoms 94
Muscle symptoms 82
Gastrointestinal symptoms 100
Painful lymphnodes 94
Hearing loss 93 82
Eye symptoms 82
Headaches 82
Brain MRI 82
Cognitive function test 94
Funduscopy 88
Limitation of daily activity 89 87 87 80 81
Days of school /work loss 83 81
Global DAS physician 83 81 88
Global DAS patient 82
ESR 83

New variables/items suggested by experts after the first round are shown in italics.

CAPS, cryopyrin-associated periodic syndromes; CINCA/NOMID, chronic infantile neurological, cutaneous, articular/neonatal onset multisystem inflammatory disease; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; FCAS, familial cold autoinflammatory syndrome; FMF, familial Mediterranean fever; MKD, mevalonate kinase deficiency; MWS, Muckle-Wells syndrome; TRAPS, TNF receptor-1-associated periodic syndrome.